Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KIT2014 in Healthy Volunteers
NCT06659757Phase 1Completed
- Sponsor
- Kither Biotech
- Start
- Oct 2024
- Primary completion
- Jul 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KIT2014 in cystic fibrosis (CF) (2 arms), sponsored by Kither Biotech. Primary endpoints: Treatment-emergent adverse events and Serious adverse events. Started Oct 2024; status: completed.
02
Drugs
KIT2014
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT06659757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06659757.